💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality business, fully valued.
Strides Pharma Science is scored on the pharma / healthcare framework. It keeps a healthy 11.5% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.22× reported profit. It throws off free cash worth 5.8% of its market value — a strong free-cash yield.
Book value has grown 13%/yr. Return on equity is an elite 18.1%. In the latest quarter profit grew 28% versus the prior quarter.
At 17× earnings, the stock sits at the 67th percentile of its own 1.6-year range — the middle of where it has historically traded. Today's price implies ~5%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 14.47 | — | — |
| P/B | 2.7 | 4.11 | better |
| EV/EBITDA | 9.75 | 19.15 | better |
| ROE | 18.05 | — | — |
| ROCE | 17.09 | 6.87 | better |
| ROA | 8.51 | — | — |
| Quick Ratio | 0.68 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 10% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
2 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -84% swing — check if it's a one-off or structural.
Operating margin has expanded from -8% to 13% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 18% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 29pp across the window.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -85% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.2× PAT — earnings are well-backed by cash; strong accrual quality. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (6% spread) — a predictable, non-seasonal revenue stream.
Profit jumped 28% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (11% → 13%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 1.6y median.
Promoters hold just 29.0% — widely held; sentiment-driven. Promoters added 1.1pp over 4 quarters — creeping acquisition signals conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.